Latest MS research news

Latest MS research news | 18 March 2014

Major stressful life events in adulthood and risk of MS

This study looked at the risk of developing MS following exposure to well-defined indicators of severe stress as a result of divorce or loss of a close family member. The results demonstrated that there was no association between these stress measures and risk of developing MS.

From MSIF

Latest MS research news | 11 March 2014

Optical coherence tomography and visual evoked potentials

Optic neuritis occurs in about 50 per cent of MS patients. This study looked at visual evoked potentials, which assess the integrity and function of the visual pathway, and optical coherence tomography, which measures the retinal nerve fibre layer thickness.

From MSIF

Latest MS research news | 11 March 2014

Diagnostic value of brain chronic black holes on T1-weighted MR images in clinically isolated syndromes

This study looked at the prevalence of non-enhancing black holes on MRI in a large population of patients with a clinically isolated syndrome and to determine if they helped to better predict conversion to clinically definite MS.

From MSIF

Latest MS research news | 11 March 2014

MiR-126: a novel route for natalizumab action?

This study shows the potential role of a particular type of protein (miR-126), which control gene expression and are involved in immunity. This particular protein was found to be down-regulated in patients treated with natalizumab, while the protein was up-regulated during relapse.

From MSIF

Latest MS research news | 04 March 2014

Tobacco smoking and excess mortality in multiple sclerosis: a cohort study

In MS patients, current smoking was associated with more than a 2.5-fold increased risk of death. Current smokers with MS had a reduction of about 10 years in their life expectancy relative to non-smokers with MS.

From MSIF

Latest MS research news | 03 March 2014

Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study

This study included data from 333 patients with MS who switched from natalizumab (Tysabri) to fingolimod. This study highlights the substantial risk of relapse during the washout period - the time between stopping one drug and starting the next.

From MSIF

Latest MS research news | 03 March 2014

Combined visual and motor evoked potentials predict multiple sclerosis disability after 20 years

The results from this study show that a combined numerical score of motor and visual evoked potentials measures allows prediction of the development of long-term clinical disability after 20 years in MS patients.

From MSIF

Latest MS research news | 25 February 2014

Investigation of outer cortical magnetisation transfer ratio abnormalities

The outer grey matter layer of the brain, called the cortex, often contains demyelinating lesions in MS patients. This study group used a specific type of MRI sequence (called magnetization transfer ratio (MTR)), to image this outer layer of the brain

From MSIF

Latest MS research news | 25 February 2014

Brain atrophy and disability progression in MS patients: A 10-year follow-up study

This prospective study looked at the association between MRI measures of global and tissue-specific damage and disability progression.

From MSIF

Latest MS research news | 25 February 2014

Cerebrospinal fluid detection of interleukin-1beta in phase of remission predicts disease progression in MS

The researchers in this study showed that the presence of a certain inflammatory protein in the spinal fluid of patients with relapsing remitting MS

From MSIF
 

Latest MS research news

Main MS research areas

Challenges of MS research

Atacicept in multiple sclerosis: a randomised, placebo-controlled, double-blind, phase 2 trial